Drug Type Small molecule drug |
Synonyms AP-003, LX-001 |
Action inhibitors, stimulants |
Mechanism Bone resorption factor inhibitors, RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors), Osteoblasts stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 2 | United States | 27 Sep 2019 | |
Breast cancer recurrent | Phase 2 | United States | 27 Sep 2019 | |
Non-Small Cell Lung Cancer | Phase 2 | United States | 27 Sep 2019 | |
Prostatic Cancer | Phase 2 | United States | 27 Sep 2019 | |
Relapsed Solid Neoplasm | Phase 2 | United States | 27 Sep 2019 | |
Solid tumor | Phase 2 | United States | 27 Sep 2019 |